MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ekir.2026.106668

Медицинская библиотека · Kidney international reports · 2026

Anti-CD38/Anti-CD20 Rescue Therapy for Posttransplant Recurrent FSGS.

Leon Juliette, Ducrocq Elise, Lafargue Marie-Camille, Bertrand Dominique, Maigret Lucie, Zaidan Mohamad, Colin Arthur Michon, Thervet Eric, Durrbach Antoine, Kamar Nassim, Schvartz Betoul, Bouvier Nicolas, Mazloum Manal, Bennani Hamza Naciri, Guezennec Manon, Es-Saleh Dalila, Troger Antoine, Burger Carole, Le Stang Marie-Bénédicte, Roger Camille, Hullekes Frank, Aubert Olivier, Zuber Julien, Riella Leonardo V, Audard Vincent, Anglicheau Dany

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Recurrent focal segmental glomerulosclerosis (FSGS, rFSGS) is a severe complication after kidney transplantation, often resistant to standard therapies and requiring prolonged apheresis. Combined depletion of plasma cells (anti-CD38) and B cells (anti-CD20) has emerged as a potential strategy; however, multicenter real-world data integrating clinical, biological, and histological characterization remain limited.

METHODS

We retrospectively studied 17 kidney transplant recipients with rFSGS treated with daratumumab (anti-CD38) administered after and/or in combination with anti-CD20 therapy across 12 French centers. Patients were clinically and histologically characterized at treatment initiation. Clinical response, safety, and longitudinal antinephrin antibody trajectories were assessed.

RESULTS

Median time from recurrence to daratumumab initiation was 5 months. All patients had previously received B-cell-depleting therapy. After the first daratumumab course (1-8 injections), 7 patients (41%) achieved complete remission (CR) and 4 (24%) achieved partial remission (PR), allowing discontinuation of apheresis in all responders. Median response time was 24 days. During a median follow-up of 8 months, 3 responders relapsed but regained remission after retreatment. Median proteinuria decreased from 3.9 g/g to 1.4 g/g at 1 month (P = 0.029). Among 11 patients tested, 3 had positive antinephrin antibodies. Two patients showed marked posttreatment declines paralleling clinical response, whereas 1 did not. Treatment was well-tolerated.

CONCLUSION

In this multicenter real-world cohort, combined plasma cell and B-cell depletion was associated with meaningful remission rates in refractory rFSGS and was accompanied by dynamic changes in antinephrin antibodies in selected cases. Prospective trials are warranted to define optimal patient selection and dosing, and to clarify its place in therapy.

Для цитирования: Leon Juliette, Ducrocq Elise, Lafargue Marie-Camille, Bertrand Dominique, Maigret Lucie, Zaidan Mohamad, Colin Arthur Michon, Thervet Eric, Durrbach Antoine, Kamar Nassim, Schvartz Betoul, Bouvier Nicolas, Mazloum Manal, Bennani Hamza Naciri, Guezennec Manon, Es-Saleh Dalila, Troger Antoine, Burger Carole, Le Stang Marie-Bénédicte, Roger Camille, Hullekes Frank, Aubert Olivier, Zuber Julien, Riella Leonardo V, Audard Vincent, Anglicheau Dany. Anti-CD38/Anti-CD20 Rescue Therapy for Posttransplant Recurrent FSGS.. Kidney international reports. 2026. DOI: 10.1016/j.ekir.2026.106668.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.